Individualized, optimized testing   

Improve outcomes through precision results

For patients with a history of Parkinson’s disease, understanding their genetic risk of developing the condition is an important first step in tailoring interventions that may delay symptom onset and progression. Genetic testing can reveal characteristics about prognosis and may help guide and customize treatment selection.

Genetic testing is also important for patients affected by early-onset illness, which is more often due to genetic causes. Although known genetic variation is present in only 10% to 15% of patients, awareness and information regarding specific genetic causes can deepen understanding about disease progression and enable elevated outcomes. 

Mayo Clinic Laboratories’ comprehensive Parkinson’s disease gene panel uses next-generation sequencing to analyze 94 genes associated with hereditary forms of the condition. Developed by a multidisciplinary team of clinicians, geneticists, and laboratory testing experts, our panel includes genes known for causing Parkinson’s disease, but also genes that increase the likelihood of developing the condition.

Key testing

PARDP    | Inherited Parkinson Disease Gene Panel, Varies

  • Uses next-generation sequencing to detect single nucleotides and copy number variants in 94 genes associated with Parkinson’s disease.
  • Establishes molecular diagnosis.
  • Identifies variants within genes known to be associated with Parkinson’s disease, enabling predictive testing for at-risk family members.
  • Includes variants associated with certain high-risk ethnic groups.

Test assesses all inherited Parkinson's disease genes

Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it.

Learn more about how to order these tests at your institution.